Scandal Erupts Over Drug Company Relationships with State Medical Boards

Which conflict-of-interest is worse? You be the judge.

1. Drug company money setting the agenda for university drug research, with publication controlled by the corporations, or;

2. Drug company funding the Federation of State Medical Boards to publish a report on the opioid drugs these companies manufacture.

Here’s a powerful piece of investigative journalism on the medical board scandal:

The Federation of State Medical Boards, often develops guidelines that serve as the basis for model policies with the stated goal of improving medical practice — but after its guideline for the use of opioids to treat chronic pain patients was adopted as a model policy, it asked Purdue Pharmaceuticals for $100,000 to help pay for printing and distribution that policy to 700,000 practicing doctors.

That $100,000 was just a small downpayment on the $3.1 million that the Federation’s foundation estimated it would cost for its campaign to get out the word about “safe” use of opioid analgesics in treatment of chronic pain.

The federation, which functions as a trade group representing some 70 allopathic and osteopathic medical boards, won’t say how much money it received from industry, but the $100,000 request was detailed in a document obtained by the Milwaukee Journal Sentinel/MedPage Today from University of Wisconsin School of Medicine and Public Health.

There’s much moreI recommend reading the entire article. And I would expect more to follow.

They say that sunlight is the best disinfectant, but some infections are so toxic that sunlight alone won’t do the job. Legal and/or legislative action seem appropriate here.